MARKET

IRWD

IRWD

Ironwood
NASDAQ
10.36
-0.01
-0.10%
After Hours: 10.36 0 0.00% 17:00 09/30 EDT
OPEN
10.44
PREV CLOSE
10.37
HIGH
10.62
LOW
10.34
VOLUME
1.84M
TURNOVER
0
52 WEEK HIGH
14.21
52 WEEK LOW
10.01
MARKET CAP
1.59B
P/E (TTM)
10.44
1D
5D
1M
3M
1Y
5Y
Will Weakness in Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Stock Prove Temporary Given Strong Fundamentals?
Ironwood Pharmaceuticals (NASDAQ:IRWD) has had a rough month with its share price down 11%. However, stock prices are...
Simply Wall St. · 09/25 13:48
Insider Sell: Ironwood Pharmaceuticals
Insider Sell: Ironwood Pharmaceuticals
MT Newswires · 09/06 16:25
Ironwood Shares Positive Top-line Data From Late-Stage Functional Constipation Candidate Study In Patients Aged 6-17 Years
Ironwood Pharmaceuticals (NASDAQ: IRWD) announced positive top-line data from its Phase 3 clinical trial evaluating LINZESS (linaclotide) 72 mcg in pediatric patients aged 6-17 with functional constipation (FC).
Benzinga · 09/06 15:09
Ironwood's Constipation Drug Shows Efficacy In Pediatric Patients
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) announced topline data from a Phase 3 trial evaluating Linzess (linaclotide) 72 mcg in pediatric patients aged 6-17 with functional constipation.
Benzinga · 09/06 13:26
AbbVie, Ironwood constipation therapy Linzess meets main goal of phase 3 trial in children
AbbVie (NYSE:ABBV) and Ironwood Pharmaceuticals' medicine (<span class="tic...
Seekingalpha · 09/06 12:41
BRIEF-Ironwood Pharmaceuticals Reports Positive Topline Data From Phase Iii Trial Of Linzess® (Linaclotide) In Pediatric Patients Aged 6-17 With Functional Constipation
BRIEF-Ironwood Pharmaceuticals Reports Positive Topline Data From Phase Iii Trial Of Linzess® (Linaclotide) In Pediatric Patients Aged 6-17 With Functional Constipation
Reuters · 09/06 11:53
Ironwood Pharmaceuticals Reports Positive Topline Data From Phase III Trial Of LINZESS (linaclotide) In Pediatric Patients Aged 6-17 With Functional Constipation; Study Met Primary And Secondary Endpoints
  – Study met primary and secondary endpoints – – Results add to body of data supporting the safety of linaclotide for this patient population – – There are currently no FDA approved
Benzinga · 09/06 11:04
Capital One Securities Initiates IRWD at Overweight with $15 Price Target
Capital One Securities Initiates IRWD at Overweight with $15 Price Target
MT Newswires · 09/02 09:50
More
About IRWD
Ironwood Pharmaceuticals, Inc. is a gastrointestinal (GI) healthcare company that is focused on the development and commercialization of GI products in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC). It operates in the human therapeutics business segment. Its product candidate LINZESS (linaclotide) is available to adult men and women suffering from IBS-C or CIC in the United States, and Mexico and to adult men and women suffering from IBS-C. Its linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC in Canada, and to adult men and women suffering from IBS-C in certain European countries. The Company’s products pipeline includes IW-3300, which is a GC-C agonist, for the potential treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis, and CNP-104 is a tolerizing immune modifying nanoparticle.

Webull offers kinds of Ironwood Pharmaceuticals, Inc. stock information, including NASDAQ:IRWD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IRWD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IRWD stock methods without spending real money on the virtual paper trading platform.